Cardiotoxicity is a well-established complication of antineoplastic agents. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more specific than conventional therapies, has revolutionized oncology therapy and dramatically changed cancer prognosis. However, some of these therapies have introduced an assortment of cardiovascular complications. At times, these devastating outcomes have only become apparent after drug approval and have limited the use of potent therapies. There is a growing need for better testing platforms, both for cardiovascular toxicity screening and for elucidating mechanisms of cardiotoxicity of approved cancer therapies.
Patel B, Gupta R, Garg J, Sablani N, Patel R, Lanier G. Microtubule inhibitors. In: Lanier GM, editor. Cardiotoxicity of chemotherapeutic agents. Hauppauge, NY: Nova Science; 2017. pp. 101-20.